BTK and mantle cell lymphoma: Li et al. investigated the molecular mechanisms of BTK inhibition with the novel molecular targeted inhibitor BGB-3111 (zanubrutinib) in MCL models.166 They found that BGB-3111 exhibits greater specificity for BTK, and it exhibits excellent efficacy in preclinical MCL cell models and PDX models, which will be helpful in promoting the progress of clinical trials.